Skip to content
MedsAcross

Medicine

Viokace 78300 units/20880 units/78300 units tablet

Available on requestPrescription onlyUS FDA

Viokace 78300 units/20880 units/78300 units tablet is a prescription medicine containing Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease for oral use, marketed by Aimmune Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store VIOKACE at room temperature 20°C to 25°C (68°F to 77°F), and protect…

Key facts

Active ingredient (INN)
Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease
Brand
Viokace
Strength
78300 units/20880 units/78300 units
Dosage form
Tablet
Route
Oral
Packs
1 bottle
Marketing authorisation holder
Aimmune Therapeutics
Manufacturer
Aimmune Therapeutics
Origin register
US FDA, United States
Storage
Store VIOKACE at room temperature 20°C to 25°C (68°F to 77°F), and protect from moisture. Brief excursions permitted up to 40°C (104°F) for 24 hours. After opening, keep the container tightly closed between uses to protect from moisture. Store and dispense VIOKACE in the original container.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3002.15Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
1 March 2021
Identifiers
RxCUI 1247379, 1247381, 1247386 +1DailyMed set ID 58bdb8de-582d-44e6-9b72-8d5a42fdf501NDC 73562-208Application BLA022542

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 bottle in 1 carton / 100 tablet in 1 bottle73562-208-10Aimmune Therapeutics1 March 2021

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease

Clinical summary

Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease is a fixed-dose combination medicine indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. MedsAcross supplies Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Pancrelipase amylase, Pancrelipase lipase and Pancrelipase protease

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Viokace 78300 units/20880 units/78300 units tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.